ACE2 and COVID-19: Some concerns have been raised regarding the long-term use of ACE inhibitors or angiotensin receptor blockers (e.g., captopril, losartan) for individuals with pre-existing cardiovascular diseases during the COVID-19 pandemic, as these drugs might upregulate ACE2 and could theoretically enhance susceptibility to SARS-CoV-2 infection and COVID-19 severity.